دورية أكاديمية

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.

التفاصيل البيبلوغرافية
العنوان: Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.
المؤلفون: Naehrlich, Lutz1 (AUTHOR), Orenti, Annalisa1,2 (AUTHOR), Dunlevy, Fiona1,3 (AUTHOR), Kasmi, Irena4 (AUTHOR), Harutyunyan, Satenik5 (AUTHOR), Pfleger, Andreas6 (AUTHOR), Keegan, Svetlana7 (AUTHOR), Daneau, Géraldine8 (AUTHOR), Petrova, Guergana9 (AUTHOR), Tješić-Drinković, Duška10 (AUTHOR), Yiallouros, Panayiotis11 (AUTHOR), Bilkova, Alena12 (AUTHOR), Olesen, Hanne Vebert13 (AUTHOR), Burgel, Pierre-Régis14 (AUTHOR), Parulava, Tsitsino15 (AUTHOR), Diamantea, Filia16 (AUTHOR), Párniczky, Andrea17,18 (AUTHOR), McKone, Edward F19 (AUTHOR), Mei-Zahav, Meir20 (AUTHOR), Salvatore, Marco21 (AUTHOR)
المصدر: Journal of Cystic Fibrosis. Jul2021, Vol. 20 Issue 4, p566-577. 12p.
مصطلحات موضوعية: *SARS-CoV-2, *CYSTIC fibrosis, *VIRUS diseases, *LUNG transplantation
مصطلحات جغرافية: EUROPE
مستخلص: • We report 130 SARS-CoV-2 cases in people with CF (pwCF) to June 2020 across Europe. • Reported incidence was higher in pwCF versus the age-matched general population. • pwCF had more hospital and intensive care admissions than the general population. • Lung-transplanted pwCF had more severe illness and needed more care. • SARS-CoV-2 can cause severe disease in pwCF justifying priority vaccination. Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination. [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:15691993
DOI:10.1016/j.jcf.2021.03.017